Online inquiry

IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10875MR)

This product GTTS-WQ10875MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets B4GALNT1 gene. The antibody can be applied in Melanoma, Neuroblastoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001276468.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2583
UniProt ID Q00973
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10875MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10241MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LFB-R603
GTTS-WQ2155MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALD-518
GTTS-WQ11889MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ10741MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ8804MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ13029MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ14424MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ10704MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-1095
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW